Literature DB >> 20925644

Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital.

Elena Ramirez1, Su H Lei, Alberto M Borobia, Enrique Piñana, Salvador Fudio, Raúl Muñoz, Armando Campos, Antonio J Carcas, Jesus Frias.   

Abstract

BACKGROUND: The first generic PPI was introduced in Spain in 2001, and since then their prescriptions have increased steadily by about 200%. AIM: To evaluate the frequency of use and the appropriateness of indications of PPIs in hospitalised patients, and possible factors predicting their use. We also evaluated relevant PPI-drug interactions and serious adverse drug reactions (SADRs).
METHODS: This was a cross-sectional, prescription-indication drug-utilisation study in hospitalised patients with follow-up until discharge. Sampling was random and stratified by services, and was calculated to obtain an error in the precision of prescription of ±4% with a 95% confidence interval with maximum variability (50%).
RESULTS: 328 patients were included; 28.65% were prescribed a PPI at admission, 82.62% were prescribed a PPI during hospitalisation, and 54.75% at discharge, with inappropriate indications in 74.47%, 61.25% and 80.24% respectively. The OR of being discharged with PPIs was 3.01(95% CI:2.17-4.18, p=0.000). The inappropriate indication most frequently seen at admission and at discharge was antiplatelet therapy. During hospitalisation it was prophylaxis for stress ulcer in patients at low risk. PPI prescription at admission remained at discharge in 75.90% of cases, 73.02% without an acceptable indication. Being >64 years old, taking >4 drugs, co-medication (NSAIDs, antiaggregation and anticoagulation), certain hospital departments and length of stay >15 days predicted 83.7% of prescriptions at discharge. Four relevant PPI-drug interactions were found, and 2 resulted in SADRs, thus the incidence per 1, 000 patients was 2.66 (Poisson 95% CI:0.62-7.23).
CONCLUSIONS: There was a very high frequency of overuse of PPIs in inpatients and outpatients. Hospitalisation did not represent an opportunity for better prescription of PPIs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20925644     DOI: 10.2174/157488410793352067

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  18 in total

Review 1.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 2.  Prescribing proton pump inhibitors: is it time to pause and rethink?

Authors:  Nimish Vakil
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

3.  Early referral for esophageal pH monitoring is more cost-effective than prolonged empiric trials of proton-pump inhibitors for suspected gastroesophageal reflux disease.

Authors:  David A Kleiman; Toni Beninato; Brian P Bosworth; Laurent Brunaud; Thomas Ciecierega; Carl V Crawford; Brian G Turner; Thomas J Fahey; Rasa Zarnegar
Journal:  J Gastrointest Surg       Date:  2013-11-09       Impact factor: 3.452

4.  Inappropriate use of proton pump inhibitors in a local setting.

Authors:  Christopher Tze Wei Chia; Wan Peng Lim; Charles Kien Fong Vu
Journal:  Singapore Med J       Date:  2014-07       Impact factor: 1.858

5.  Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals.

Authors:  Marcello Maggio; Andrea Corsonello; Gian Paolo Ceda; Chiara Cattabiani; Fulvio Lauretani; Valeria Buttò; Luigi Ferrucci; Stefania Bandinelli; Angela Marie Abbatecola; Liana Spazzafumo; Fabrizia Lattanzio
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

6.  Research Into the Effect of Proton Pump Inhibitors on Lungs and Leukocytes.

Authors:  Orhan Ozatık; Fikriye Yasemin Ozatık; Yasemin Teksen; Ilknur Dag; Suna Saygılı; Ahmet Koçak
Journal:  Turk J Gastroenterol       Date:  2021-12       Impact factor: 1.555

7.  Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea.

Authors:  Karl Weiss; Thomas Louie; Mark A Miller; Kathleen Mullane; Derrick W Crook; Sherwood L Gorbach
Journal:  BMJ Open Gastroenterol       Date:  2015-03-02

8.  Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy.

Authors:  Ophélie Dos Santos-Schaller; Sandrine Boisset; Arnaud Seigneurin; Olivier Epaulard
Journal:  Springerplus       Date:  2016-04-11

9.  Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines.

Authors:  Nathalie Vernaz; Victoria Rollason; Liene Adlere; Christophe Combescure; Antoine Poncet; Pascal Bonnabry; Jules Desmeules
Journal:  Pharmacol Res Perspect       Date:  2016-04-21

10.  Multimorbidities and Overprescription of Proton Pump Inhibitors in Older Patients.

Authors:  Anne Delcher; Sylvie Hily; Anne Sophie Boureau; Guillaume Chapelet; Gilles Berrut; Laure de Decker
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.